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A meta-analysis of the effect size of rheumatoid
arthritis on left ventricular mass: comment on the
article by Rudominer et al
To the Editor:
We appreciate the work of Rudominer et al, who
recently published a report describing the association of rheu-
matoid arthritis (RA) with increased left ventricular mass (1).
The findings of Rudominer and colleagues are consistent with
the findings of our own previous study of RA patients, which is
cited by the authors (2). Patients with RA have both structural
and functional left ventricular involvement. In these patients,
we have previously demonstrated that diastolic dysfunction
(detected as impaired relaxation abnormalities during left
ventricular filling) is directly correlated with structural changes
in the left ventricle, specifically, changes involving left ventric-
ular mass, interventricular septal thickness, and left ventricular
posterior wall thickness (2). In RA patients, these all seem to
be features of the systemic disease process, and diastolic
dysfunction seems to be a consequence of left ventricular
structural changes. However, it is probable that these findings
only partially explain the cardiovascular morbidity in RA.
Indeed, in a study of RA patients (with no exclusion
criteria), we observed a peculiar cardiac picture among pa-
tients who had no symptoms of cardiac disease (3). The
population of RA patients in that study seemed to share 3
characteristics: minimal posterior pericardial effusion, alter-
ation of the aortic root (detected as an increased prevalence of
Valsalva sinus aneurysms), and both valvular and valvular cord
thickening. However, even though left ventricular mass was
greater overall in the RA group, the difference was not
statistically significant in patients versus controls. We believe
that heart involvement in RA results from the disease’s
systemic inflammatory process, which explains the high rates of
cardiac mortality in RA patients. Thus, we completely agree
with the conclusions discussed by Rudominer et al and think
that the collective scientific community has achieved an im-
portant goal in demonstrating that different populations with
RA (both Mediterranean [2,3] and North American [1]) have
the same clinical cardiac features (i.e., a higher left ventricular
mass index and abnormalities consistent with impaired left
ventricle relaxation).
We undertook a meta-analysis of previously published
reports (1–4) to summarize the effect size of RA on left
ventricular mass index in patients compared with healthy
controls. We searched for data pertaining to left ventricular
mass index, which had been determined using echocardiogra-
phy. Unfortunately, in the studies by Arslan et al (5) and
Gonzalez-Juanatey et al (6), left ventricular mass index was not
calculated; therefore, we excluded these studies from our
analysis. We computed the modified Glass statistic using
pooled sample standard deviation and Cochran’s Q statistic.
The pooled mean effect size estimate was calculated according
to methods described by Hedges and Olkin (7). Figure 1 shows
the pooled estimation of effect size using a fixed-effects model
Figure 1. Forest plot of the effect size in the meta-analysis, using a
fixed-effects model. Squares represent the effect sizes in the previous
studies. The diamond and dotted line represent the pooled effect size
in the meta-analysis. Horizontal lines represent the 95% confidence
interval (95% CI). The Glass statistic (mean difference standardized
by pooled standard deviation) and 95% CI are shown as the pooled
mean effect size estimate. For the overall fixed-effects model, P 
0.0001.
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(7). This model was used since there was low interstudy vari-
ation. The data from our meta-analysis support the findings of
Rudominer et al, and help to describe the effect of RA on the
heart. In conclusion, we believe that left ventricular structural
and functional changes are one of the established clinical
features of RA, and the challenge will now be to find ways to
utilize this information both to optimize clinical monitoring
and to reduce cardiovascular mortality in RA patients.
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Aortic stiffness and left ventricular hypertrophy in
rheumatoid arthritis: comment on the article by
Rudominer et al
To the Editor:
In the recent article by Rudominer et al (1), the
authors reported an association of rheumatoid arthritis (RA)
with increased left ventricular (LV) mass but not with reduced
ejection fraction. Rudominer and colleagues also suggested
that a pathophysiologic link might exist between chronic
inflammation and LV hypertrophy, even though LV systolic
function was preserved in their study population.
LV hypertrophy might be useful in predicting cardio-
vascular events independent of traditional risk factors. In
addition, arterial stiffness has been described as an indepen-
dent predictor of cardiovascular mortality both in patients with
cardiovascular disease and in the general population (2–4).
In a population of patients with RA, we investigated
both ventricular mass and aortic elasticity, which is considered
an important determinant of LV function and coronary blood
flow. Aortic elasticity was assessed using a 2-dimensional
guided M-mode evaluation of the systolic aortic diameter (Ds)
and the diastolic aortic diameter (Dd) at a location 3 cm above
the aortic valve; using simultaneous electrocardiography, Dd
was measured at the peak of the R wave, and Ds was measured
at the point of maximal anterior motion of the aortic wall. For
both diameters, 5 measurements were taken and then aver-
aged. Indices of aortic elasticity were calculated as follows:
aortic strain  100(Ds  Dd)/Dd; aortic distensibility 
(2[Ds  Dd]/Dd[PP]) (given as cm
2/dyn 106) where PP is
pulse pressure (calculated as Ps  Pd); and aortic stiffness 
ln(Ps/Pd)/([Ds  Dd]/Dd) where Ps and Pd are systolic and
diastolic blood pressures, respectively, measured in mm Hg,
and where ln(Ps/Pd) refers to the natural logarithm of the
relative pressure.
In a population of 93 randomly enrolled RA patients,
we observed increased mean SD LVmass (101 29 gm/m2),
decreased aortic strain and distensibility indices (8  5% and
3.2  2.5 cm2/dyn 106, respectively), and an increased
stiffness index (10.5  9.7). From this cohort, we then selected
35 patients who had no hypertension, valve disease, or history
of cardiovascular disease (mean  SD age 57.8  7.7 years,
mean  SD RA disease duration 10  8 years). In these
patients, we observed increased mean  SD LV mass (92 
53.1 gm/m2), decreased aortic strain and distensibility indices
(9 3.8% and 3.6 0.8 cm2/dyn 106, respectively), and an
increased stiffness index (7.6  2.6).
Patients were then divided into 2 subgroups based on
their C-reactive protein levels (0.5 mg/dl versus 0.5 mg/dl);
LV mass was not significantly different between the 2 groups.
LV mass and other morphologic and functional cardiac para-
meters were compared. In a univariate analysis, indexed LV
mass tended to correlate with aortic distensibility, but this was
not significant (P  0.069). In a multivariate analysis, LV mass
significantly correlated with aortic distensibility (P  0.04) but
only tended to correlate with aortic strain (P  0.06).
The stiffening of the aorta and other central arteries
represents a potential risk factor for increased cardiovascular
morbidity and mortality (2–4). Furthermore, an association
between impaired aortic elasticity and LV hypertrophy has
been demonstrated in previous studies (5,6). Our findings
confirm those of Rudominer and colleagues (1) and demon-
strate an association between some aspects of impaired aortic
elasticity and increased LV mass in RA patients. These
findings suggest that patients with RA could have preclinical
atherosclerosis, even without having hypertension or other
cardiovascular risk factors. A decrease in aortic elasticity could
influence the natural history of RA and contribute to the
development of cardiovascular disease and left ventricular
dysfunction.
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